Wolverine Legal Status, FDA 503A Category, and Compounding Access

The direction of travel: an active FDA review in 2026

Wolverine legal status starts with momentum. Access to the BPC-157 TB-500 components is under active FDA review, and it may expand in 2026. The FDA's Pharmacy Compounding Advisory Committee (PCAC) is scheduled to meet on July 23-24, 2026, and both of the blend's constituents — BPC-157 and TB-500 — are on that meeting's published agenda, listed as bulk drug substances "being considered for inclusion on the 503A Bulks List" ^[14].

That is a real, dated, citable event, and it is genuinely forward-leaning: the two peptides are in front of the committee that advises FDA on which substances may be compounded. It is also, precisely, a scheduled discussion — an advisory step in an ongoing evaluation, not a decision. No reclassification has occurred, none is dated, and none is certain. PCAC discussion is advisory; the listing decision is FDA's, made later by rulemaking ^[13][14]. This page describes the current status accurately and the scheduled review honestly, and it claims nothing about the outcome.

The current FDA 503A status of the Wolverine components

FDA's page, current as of April 22, 2026, no longer shows either Wolverine component in Category 2: each nomination had been withdrawn by its nominator ^[12]. The placement took effect with the FDA's September 29, 2023 update to the list of bulk drug substances nominated for use under Section 503A ^[12].

The FDA's list entries name them directly. BPC-157 (evaluated as "BPC-157 (free base)" and "BPC-157 acetate") is shown with nominations withdrawn by the nominators; FDA still cites concerns including potential immunogenicity for certain routes of administration and complexities with peptide-related impurities and active-ingredient characterization ^[12]. TB-500 appears in the entry "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" — the FDA's own listing establishes that TB-500 is the LKKTETQ fragment associated with thymosin beta-4 — but its nomination was withdrawn by the nominator, while FDA continues to cite potential immunogenicity for certain routes and a lack of important safety information ^[12]. The same withdrawal status covers both legs of the blend: the current table omits each from Category 2, and FDA's staff proposed against listing both for the July 23-24, 2026 advisory-committee meeting; FDA has published no record of the committee's votes as of September 17, 2026 ^[12][14].

That enforcement-discretion statement described Category 2; after the nominations were withdrawn, FDA has not said how a 503A compounder should treat those entries ^[13]. Compounding-pharmacy access to these peptides is, on that basis, currently restricted. Neither constituent is an FDA-approved drug, and the blend has no approved therapeutic indication.

How legally compounded peptide access works

U.S. drug compounding runs through two sections of the Federal Food, Drug, and Cosmetic Act. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered "outsourcing facilities" that compound larger batches under cGMP-style oversight and FDA inspection ^[13].

In general terms, a legally compounded medication follows one pathway. A patient is evaluated by an appropriately licensed prescriber — in person or through a compliant telehealth encounter — who determines whether a compounded preparation is clinically appropriate. If it is appropriate and lawful, the prescriber issues a valid, patient-specific prescription. That prescription is then dispensed by a state-licensed 503A compounding pharmacy, or, for office and batch use, sourced from an FDA-registered 503B outsourcing facility ^[13].

Telehealth is one channel for the prescriber-evaluation step, not a separate legal status. It does not expand which substances may be compounded and does not remove the need for a legitimate clinical evaluation and a valid prescription. And there is a hard ingredient-eligibility caveat that governs the whole pathway: a compounder may use a bulk drug substance only if that substance has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list. A substance the FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands ^[13]. That is the caveat the current Category 2 placement of both Wolverine components turns on.

Are BPC-157 and TB-500 FDA approved or banned by WADA?

Neither is FDA-approved for human use, and the blend has no approved indication ^[12]. Separately, in sport, both constituents are prohibited by the World Anti-Doping Agency: BPC-157 falls under the S0 non-approved-substances category, and TB-500 / thymosin beta-4 falls under prohibited peptide and growth-factor categories. The blend is banned in and out of competition for the relevant classes — its WADA prohibited status is independent of the FDA compounding question and applies regardless of how the 503A review resolves.

Can you get BPC-157 from a compounding pharmacy?

Currently, access is restricted. FDA placed BPC-157 in Category 2 in its September 29, 2023 list update, but its page current as of April 22, 2026 shows that the nomination was withdrawn and no longer lists BPC-157 in Category 2; FDA has not stated how a 503A pharmacy should apply that withdrawal ^[12][13]. BPC-157 is also on the FDA's scheduled July 23-24, 2026 advisory-committee agenda as a candidate for the 503A bulks list, which means its evaluation is ongoing rather than resolved ^[14]. No reclassification has occurred or been dated; the present-tense status is restricted.

What is the FDA 503A status of the Wolverine blend?

Both constituents are unapproved for human use. FDA's September 29, 2023 update placed BPC-157 in Category 2 for 503A compounding and did the same for TB-500 — listed by the FDA as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" — but the current page records both nominations as withdrawn and no longer carries either substance in Category 2 ^[12]. Both are on the FDA's scheduled July 23-24, 2026 PCAC agenda as substances being considered for the 503A bulks list ^[14]. This is Wolverine legal status and FDA 503A category in summary: both nominations were withdrawn and the current table omits both constituents from Category 2; FDA has not answered what that leaves a compounding pharmacy able to do.

General information, not advice

This page is general information about the regulatory landscape. It is not medical or legal advice, and it is not an offer to sell or supply any substance. It names no pharmacy, clinic, telehealth provider, or vendor; it provides no dosing, administration instructions, or protocols; and it describes no way to obtain a restricted substance outside the lawful framework. Where it states a present-tense status, that status is cited to the FDA. Where it references the July 2026 advisory-committee meeting, it does so only as a scheduled discussion of substances under evaluation — never as a decision, a reclassification, or an outcome ^[12][13][14].